BCRX strange pm behavior considering what sounds like good news - went up and now down on this: beats by $0.18, beats on revs; reports statistically significant and clinically meaningful reductions in attack frequency from an interim analysis of its ongoing APeX-1 clinical trial in patients with HAE BCRX
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.